21st Century Oncology chooses Elekta for replacement of radiation therapy devices
Hospitals in seven U.S. states to upgrade to Elekta’s Versa HD linear accelerators
STOCKHOLM, November 21, 2017 – Elekta (EKTA-B.ST) announces that 21st Century Oncology, the largest radiation oncology provider in the U.S., will replace several of its existing linear accelerators, as well as treatment planning software and oncology information systems, with advanced cancer treatment solutions from Elekta.
The agreement includes Elekta’s Versa HD™ linear accelerators, which combines high definition dynamic radiosurgery and precision radiation therapy treatments throughout the body in a single platform. It also includes Elekta’s MOSAIQ® oncology information system – the Best in KLAS award winner – that enables optimization in health care practices through intelligent automation and actionable analytics. 21st Century Oncology will also upgrade to Monaco®, a state-of-the-art treatment planning solution that powers efficient high definition treatment planning with gold-standard accuracy.
Gustavo Olivera, PhD, 21st Century Oncology’s Chief Technology Officer, and Dr. Arie Dosoretz, a 21st Century Oncology member of the Office of the Chief Medical Officer, who oversees clinical operations, says: "Elekta’s portfolio is well aligned with our strategic needs. Our partnership offers us a tremendous opportunity to update our domestic and international fleet of machines and continue to adapt our clinical offerings to an ever-evolving field. We are excited to implement our vision together now and in the years to come."
Dr. Constantine Mantz, 21st Century Oncology’s Chief Medical Officer, says: “Our ambition is to provide state-of-the-art radiation therapy. Upgrading to Elekta’s innovative technology is as much an investment in our patients as it is in equipment. With this suite of solutions, we will be able to deliver high quality care for our patients in a highly efficient and integrated manner for our treatment centers.”
Peter Gaccione, EVP Region North America at Elekta, says: “We are very happy that 21st Century Oncology has chosen Elekta, a company that shares and supports their goal to offer the most advanced cancer treatment in a patient-centric setting focused on continuous innovation.”
USD 22 million has been booked in the second quarter of Elekta’s fiscal year 2017/18. First deliveries of the new order are scheduled to begin in April, 2018, to centers in the USA.
To learn more about these solutions, visit:
Versa HD http://www.versahd.com/
MOSAIQ http://www.elekta.com/mosaiq
Monaco http://www.elekta.com/monaco
# # #
For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242, e-mail: gert.vansanten@elekta.com
Time zone: CET: Central European Time
Tobias Bülow, Director Financial Communications, Elekta AB
Tel: +46 722 215 017, e-mail: tobias.bulow@elekta.com
Time zone: CET: Central European Time
This is information that Elekta AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 07:30 CET on November 21, 2017. (REGMAR)
About Elekta
Elekta is proud to be the leading innovator of equipment and software used to improve, prolong and save the lives of people with cancer and brain disorders. Our advanced, effective solutions are created in collaboration with customers, and more than 6,000 hospitals worldwide rely on Elekta technology. Our treatment solutions and oncology informatics portfolios are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, and to drive cost efficiency in clinical workflows. Elekta employs 3,600 people around the world. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm. www.elekta.com
Tags: